Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations

09/16/2021 | 10:12am EDT

CARLSBAD, Calif. - The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive metastatic non-small cell lung cancer (mNSCLC) who are candidates for EXKIVITY (mobocertinib), a targeted drug developed by Takeda Pharmaceutical Company Limited ('Takeda').

EXKIVITY is a small-molecule tyrosine kinase inhibitor (TKI) designed to selectively target EGFR Exon20 insertion mutations. It received approval by the FDA on September 15, 2021 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR Exon20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under Accelerated Approval based on overall response rate and duration of response demonstrated in the platinum-pretreated population of the Phase 1/2 trial of EXKIVITY. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

'Without proper and timely diagnoses, patients with EGFR Exon20 insertion mutations don't have access to therapies that can most effectively treat their disease,' said Dion Warren, vice president, head of U.S. Oncology Business Unit at Takeda Oncology. 'We're pleased to partner with Thermo Fisher to identify and address the unmet needs of patients with this rare cancer.'

Lung cancer is the leading cause of cancer death among both men and women in the United States, and non-small cell lung cancer accounts for about 80 to 85 percent of all lung cancer cases.[i] Additionally, EGFR-positive mutations are observed in up to 18 percent of lung cancer cases in the U.S., offering an opportunity to identify and group patients based on this biomarker.[ii] While EGFR mutations are an important therapeutic target, there is a gap in therapies available for EGFR Exon20 insertion mutations,[iii] which affects approximately 1-2 percent of patients with NSCLC.[iv]

Conventional PCR methods can miss 50 percent or more of EGFR Exon20 insertion mutations[v],[vi], thus prompting diagnostic molecular testing with next-generation sequencing (NGS) technology. Testing with NGS is important for early identification and appropriate characterization of tested patients.

'EXKIVITY offers new hope to previously treated patients with mNSCLC and EGFR Exon20 insertion mutations, who usually do not respond well to other available treatments,' said Garret Hampton, president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific. 'FDA approval of the Oncomine Dx Target Test as a companion diagnostic for EXKIVITY will allow clinicians to identify key biomarkers in patients who could benefit from this targeted therapy. Working closely with Takeda to scale the clinical adoption of the test as a companion diagnostic for EXKIVITY is an important next step to enabling precision medicine and potentially improving outcomes of lung cancer patients.'

Oncomine Dx Target Test simultaneously evaluates 23 genes associated with NSCLC. The FDA first approved the test as a CDx in 2017 and it is now approved for five targeted therapies for NSCLC and one targeted therapy for cholangiocarcinoma in the U.S. The test has also been approved by Japan'sMinistry of Health, Labour and Welfare (MHLW) as a CDx for five biomarkers - EGFR, ALK, ROS1, BRAF, and RET - associated with 10 targeted therapies for NSCLC. The test is currently approved and reimbursed by government and commercial insurers in more than 15 countries, including the U.S., multiple European nations, Japan, South Korea and the Middle East, and covering more than 550 million lives globally.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Contact:

Mauricio Minotta

Phone: 760-805-5266

Email: mauricio.minotta@thermofisher.com

Jen Heady

Phone: 617-275-6547

Email: jheady@greenough.biz

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
TAKEDA PHARMACEUTICAL COMPANY LIMITED -0.81% 3165 End-of-day quote.-15.71%
THERMO FISHER SCIENTIFIC 1.10% 619.64 Delayed Quote.30.61%
All news about THERMO FISHER SCIENTIFIC
10:45aGoldman Sachs Adjusts Price Target for Thermo Fisher Scientific to $720 From $690, Main..
MT
10:43aSVB Leerink Adjusts Thermo Fisher Scientific's Price Target to $685 from $675, Maintain..
MT
10:43aBaird Adjusts Price Target on Thermo Fisher Scientific to $657 From $635, Keeps Outperf..
MT
10:24aUBS Lifts Price Target on Thermo Fisher Scientific to $700 From $670, Maintains Buy Rat..
MT
06:29aCitigroup Adjusts Thermo Fisher Scientific's Price Target to $715 From $700, Reiterates..
MT
10/27Today on Wall Street: It’s a numbers game
10/27Thinking about trading options or stock in Thermo Fisher Scientific, Bristol-Myers Squi..
PR
10/27Health Care Stocks Mixed Premarket Wednesday
MT
10/27Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2022
CI
10/27Equities Point to Mixed Open With Futures Little Changed in US Pre-Bell Trading; Asia, ..
MT
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2021 37 132 M - -
Net income 2021 7 610 M - -
Net Debt 2021 26 262 M - -
P/E ratio 2021 31,9x
Yield 2021 0,16%
Capitalization 241 B 241 B -
EV / Sales 2021 7,19x
EV / Sales 2022 6,59x
Nbr of Employees 80 000
Free-Float 89,6%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 612,29 $
Average target price 659,73 $
Spread / Average Target 7,75%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors